PANBELA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4102 USD | +7.58% |
|
+0.05% | -97.76% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Panbela Therapeutics Fou...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.
Calendar
2024-05-15
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4102
USD
Average target price
15
USD
Spread / Average Target
+3,556.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -97.76% | 1.99M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- SNBP Stock
- News Panbela Therapeutics, Inc.
- Transcript : Panbela Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024
